TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00995293
Drug: 5-FLUOROURACIL
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT03847506
Drug: Candesartan cilexetil/Amlodipine besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
Study: NCT03847506
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
Study: NCT03041506
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml.
Study: NCT03041506
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
Study: NCT03041506
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
Study: NCT04140578
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: inject from iv drip before endoscopic cyanoacrylateinjection obliteration
Study: NCT01195662
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, once daily, Up to 12 weeks
Study: NCT01195662
Drug: Placebo matching Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 0 mg, once daily, Up to 12 weeks
Study: NCT00139243
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00139243
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00139243
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00942994
Drug: Aliskiren/Amlodipine
Normalized name: ALISKIREN/AMLODIPINE
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)
Study: NCT00385437
Drug: Mirtazapine Treatment
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01330108
Drug: ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
Study: NCT00004802
Drug: dichlorphenamide
Normalized name: Dichlorphenamide
DrugBank: Diclofenamide (DB01144)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02049541
Drug: PI3K inhibitor BKM120
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
Study: NCT00865540
Drug: methylcellulose 0.5%
Normalized name: METHYLCELLULOSE 0.5% SOLN,OPH
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 8h two days before surgery
Study: NCT03052400
Drug: Mifepristone 600 mg daily
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoid receptor antagonist
Study: NCT02506803
Drug: NAC-GEMABR
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
Study: NCT02314637
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin for 52 weeks
Study: NCT04126278
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg of dexamethasone
Study: NCT00213538
Drug: Response to anakinra associated with methotrexate
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00970684
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 on day 1
Study: NCT00970684
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m2 on days 1, and 8,
Study: NCT03540836
Drug: Relacorilant (3x100 mg softgel capsules)
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
Study: NCT03540836
Drug: Relacorilant (3x100 mg hard-shell capsules)
Normalized name: Hard Gelatin Capsule Shell
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
Study: NCT03540836
Drug: Relacorilant (6x50mg hard-shell capsules)
Normalized name: Hard Gelatin Capsule Shell
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
Study: NCT02743598
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02663713
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60mg twice daily
Study: NCT02663713
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg once daily
Study: NCT03539549
Drug: Abicipar pegol
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
Study: NCT03622918
Drug: colistin and rifampin combination therapy
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
Study: NCT03622918
Drug: colistin monotherapy
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: . Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
Study: NCT02230670
Drug: IDN-6556
Normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BID
Study: NCT00826176
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
Study: NCT00387868
Drug: cisplatin and etoposide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33
Study: NCT02385422
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study: NCT02385422
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study: NCT02950467
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One individual oral psilocybin treatment session
Study: NCT00025480
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025480
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00025480
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01713101
Drug: Early intravenous tranexamic acid administration
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.
Study: NCT01396447
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine was supplied in capsules.
Study: NCT03181646
Drug: citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
Study: NCT03002025
Drug: JNJ-64304500
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-64304500 as SC injection.
Study: NCT00605787
Drug: Tetradecylthioacetic acid (TTA)
Normalized name: Tartaric Acid
DrugBank: Tetradecylthioacetic acid (DB18802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg capsules once daily for 28 days
Study: NCT03966339
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
Study: NCT02794675
Drug: Cesium 131
Normalized name: Cesium
DrugBank: Cesium (DB15392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
Study: NCT01536067
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT00861705
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00861705
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02922686
Drug: Flucloxacillin
Normalized name: Flucloxacillin
DrugBank: Flucloxacillin (DB00301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
Study: NCT02922686
Drug: Phenoxymethylpenicillin
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
Study: NCT00437294
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
Study: NCT01149174
Drug: Mitomycin-C 40 mg
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical instillation of Mitomycin-C
Study: NCT04089657
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg qd, oral, taken half an hour after a meal
Study: NCT04089657
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg intravenously on day 1
Study: NCT02027831
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01362231
Drug: GS-6624
Normalized name: GS-6624
DrugBank: Simtuzumab (DB12152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
Study: NCT04115800
Drug: Liposomal Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
Study: NCT03289182
Drug: MabThera
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT03843671
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy
Study: NCT01756170
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01756170
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00616304
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
Study: NCT00033267
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01646268
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period
Study: NCT00058994
Drug: anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02933684
Drug: Seromycin
Normalized name: Seromycin
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
Study: NCT04655794
Drug: 3HP
Normalized name: OMS-103HP
DrugBank: OMS-103HP (DB05303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients taking 3HP under directly observed preventive therapy (DOPT) program
Study: NCT04364984
Drug: Angiotensin Receptor Blockers
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: routine drug intake
Study: NCT01307189
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium diskus inhalation powder, 18ug, once daily
Study: NCT02105961
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
Study: NCT00474994
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00461591
Drug: Apaziquone
Normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
Study: NCT02660489
Drug: OC459
Normalized name: Olcegepant
DrugBank: Olcegepant (DB04869)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03723967
Drug: Durvalumab with Carboplatin/Paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
Study: NCT03248791
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
Study: NCT03248791
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
Study: NCT04409860
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
Study: NCT03170180
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib 37.5mg daily
Study: NCT03170180
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg daily
Study: NCT03170180
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400mg daily
Study: NCT00852839
Drug: 552-02
Normalized name: calcifediol 0.02 MG
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
Study: NCT00961909
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: stable dose
Study: NCT00530387
Drug: 19 organic sunscreen filters and 5 topical NSAIDs
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01457690
Drug: Tocofersolan
Normalized name: tocofersolan
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a daily dose of vitamin E for 4 months:50 IU/kg
Study: NCT01457690
Drug: tocopherol alpha
Normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a daily dose of vitamin E for 4 months:50 IU/kg
Study: NCT03407716
Drug: American Ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01457690
Drug: Tocofersolan and tocopherol alpha
Normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
Study: NCT01256632
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
Study: NCT01700387
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
Study: NCT01528839
Drug: L-Thyroxine
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
Study: NCT05170217
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled cannabis containing 10mg THC
Study: NCT05170217
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled cannabis containing 10mg CBD
Study: NCT05170217
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled cannabis containing 20mg CBD
Study: NCT05170217
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled cannabis containing 30mg CBD
Study: NCT01519635
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.